CNS Neurol Disord Drug Targets. 2010 Apr;9(2):129-31. doi: 10.2174/187152710791012008.
Few topics in the field of Alzheimer's disease (AD) research have brought about the level of excitement and interest as the role of inflammation and immunity in the pathobiology and treatment of the disease. In this special issue of the journal, experts in the field give their views on how inflammatory processes and the immune system intersect- at both etiological and treatment levels- with disease biology. Collectively, nearly three decades of work are covered in this special issue, beginning with the first epidemiologic studies that showed an inverse risk relationship between AD and use of non-steroidal anti-inflammatory drugs, and ending with "immunotherapy" approaches and recent studies examining the roles of innate immune cells including microglia and peripheral mononuclear phagocytes in AD. Despite considerable work in this area, many important questions remain concerning the nature and timing of immune/inflammatory responses in the context of AD, and at what point and how to therapeutically intervene.
在阿尔茨海默病(AD)研究领域,几乎没有哪个话题能像炎症和免疫在疾病的病理生物学和治疗中的作用那样引起如此高的关注度和兴趣。在本期杂志的特刊中,该领域的专家就炎症过程和免疫系统如何在病因学和治疗水平上与疾病生物学相互作用发表了自己的看法。本期特刊涵盖了近 30 年的工作,从最初的流行病学研究开始,这些研究表明 AD 与非甾体抗炎药的使用呈负相关风险关系,一直到“免疫疗法”方法以及最近研究检查先天免疫细胞(包括小胶质细胞和外周单核吞噬细胞)在 AD 中的作用。尽管在这一领域已经开展了大量工作,但关于 AD 背景下免疫/炎症反应的性质和时间,以及在什么时间点以及如何进行治疗性干预,仍有许多重要问题悬而未决。